Saturday 17 October 2026
Export SMMT’s income statement to Excel — free account
Summit Therapeutics PLC
SMMT Healthcare Biotechnology
Summit Therapeutics PLC’s revenue for fiscal 2022 (year ended December 2022) was $705,000.00. In the quarter to June 2026, EPS grew 63.2% and free cash flow fell 112.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
14.63
0.74
−4.81%
Follow SMMT
| Jan '18 | Dec '18 | Jan '19 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | 3 | 3 | 3 | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.60 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
P/S ratio |
30.42 | 0.57 | 0.20 | 92.88 | 379.96 | 195.86 | 1,371.18 | — | — | — |
Altman Z-Score |
(0.16) | — | 0.58 | (0.60) | 4.72 | 1.63 | 0.88 | — | — | — |
Altman Z″-Score (non-manufacturers) |
(4.19) | — | 2.91 | 1.97 | (2.24) | (6.67) | 3.76 | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
P/Operating CF |
(9.40) | (3.72) | (0.64) | (4.39) | (40.99) | (38.60) | 186.22 | — | — | — |
Beneish M-Score |
— | — | — | 24.95 | (2.63) | (2.53) | (5.00) | — | — | — |
P/B ratio |
13.98 | 0.52 | 0.41 | 0.67 | 4.11 | 4.25 | 7.63 | — | — | — |
Price to Tangible BV |
0.00 | 0.95 | 0.58 | 0.82 | 4.96 | 5.00 | 7.74 | — | — | — |
EV/Sales |
26.00 | 0.06 | (0.11) | (19.12) | 302.81 | 156.22 | 1,152.64 | — | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.42 | 0.00 | 0.00 | 0.00 | — | — | — |
EV/Operating CF |
(3.25) | (0.07) | 0.28 | 0.24 | (5.41) | (3.89) | (19.54) | — | — | — |
EV/FCF |
(3.19) | (0.07) | 0.28 | 0.23 | (5.35) | (3.87) | (19.17) | — | — | — |
Quick Ratio |
1.89 | 1.29 | 3.63 | 5.68 | 4.33 | 3.75 | 16.92 | 9.30 | 10.15 | 9.87 |
Current Ratio |
1.89 | 1.58 | 3.63 | 5.78 | 4.41 | 3.80 | 16.93 | 9.30 | 10.15 | 9.87 |
Net Debt/EBITDA |
1.60 | 0.83 | (3.45) | 2.45 | 1.30 | 0.86 | 2.21 | 0.14 | 1.83 | 0.65 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.44% | 0.07% | 0.00% | 74.46% | 49.27% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 3.90 | 1.29 | 0.00 | 0.00 |
Asset Turnover |
0.56 | 0.22 | 0.73 | 0.01 | 0.01 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
2.06 | 0.73 | (3.56) | 0.71 | 0.91 | 0.82 | 0.53 | 0.12 | 0.64 | 0.30 |
Capex/Depreciation |
(1.95) | 0.00 | (0.11) | (0.21) | (0.21) | (0.12) | (0.25) | 0.49 | (1.56) | (4.50) |
Interest Coverage |
(11.02) | 0.00 | 15.69 | (4,905.89) | (13,298.25) | — | — | (37.04) | (26.02) | — |
| (219.48%) | (630.66%) | 38.47% | (43.05%) | (66.57%) | (108.89%) | (75.05%) | (601.85%) | (94.90%) | (206.10%) | |
| (15.79%) | (35.72%) | 12.80% | (33.19%) | (53.03%) | (82.09%) | (20.26%) | (141.83%) | (69.32%) | (181.94%) | |
ROIC |
0.00% | 0.00% | 26.51% | (111.17%) | (253.57%) | (468.69%) | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(40.16%) | (132.47%) | 21.83% | (43.88%) | (76.92%) | (122.41%) | (12.73%) | (362.77%) | (57.89%) | (166.51%) |
Average Days of Receivables |
226.71 | 300.10 | 168.66 | 7,067.64 | 8,375.48 | 4,907.02 | 3,944.59 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
113.97% | 233.53% | 91.08% | 5,357.87% | 6,194.65% | 4,718.19% | 7,375.74% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
47.20% | 79.55% | 28.69% | 1,518.03% | 2,236.28% | 1,305.20% | 3,793.33% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.32 | 0.32 | 0.21 | 0.16 | 0.13 | 0.11 | 0.00 | 0.01 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
6.32% | 0.00% | 11.03% | 113.73% | 205.35% | 707.79% | 1,694.75% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
(0.06) | 1.01 | 1.70 | 1.19 | 0.20 | 0.19 | 0.12 | — | — | — |
Graham Number |
0.00 | 0.00 | 12.75 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Earnings Yield |
(8.87%) | (61.67%) | 166.38% | (57.94%) | (16.20%) | (35.69%) | (8.90%) | — | — | — |
Free Cash Flow Yield |
(26.75%) | (154.07%) | (197.77%) | (88.61%) | (14.91%) | (20.62%) | (4.38%) | — | — | — |
Revenue per Share |
2.53 | 0.08 | 3.33 | 0.02 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(1.46) | (0.10) | (2.07) | (0.63) | (0.69) | (0.55) | (0.22) | (0.12) | (0.20) | (0.43) |
Capex per Share |
(0.05) | 0.00 | (0.01) | (0.01) | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(1.51) | (0.10) | (2.08) | (0.64) | (0.70) | (0.55) | (0.22) | (0.12) | (0.20) | (0.43) |
Cash per Share |
2.00 | 0.14 | 2.08 | 1.94 | 0.96 | 0.55 | 3.35 | 0.30 | 0.57 | 0.95 |
Shareholders Equity per Share |
0.98 | (0.02) | 3.29 | 2.40 | 1.14 | 0.63 | 0.66 | 0.13 | 0.54 | 0.88 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.98 | (0.02) | 3.29 | 2.40 | 1.14 | 0.63 | 0.66 | 0.13 | 0.54 | 0.88 |
Free Cash Flow |
(19.74) | (19.08) | (35.71) | (21.10) | (48.53) | (72.89) | (42.21) | (76.66) | (142.24) | (323.59) |
Working Capital |
22.05 | 18.66 | 44.93 | 65.86 | 67.78 | 71.69 | 617.93 | 169.31 | 382.02 | 647.31 |
Capital Expenditures |
(0.62) | (0.62) | (0.17) | (0.34) | (0.42) | (0.31) | (0.62) | 0.10 | (0.14) | (0.66) |
Net Current Asset Value |
(10.67) | (30.23) | 39.15 | 62.24 | 64.63 | 67.22 | 119.20 | 64.46 | 376.94 | 627.98 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.37 | 0.00 | 0.00 | 0.00 | — | — | — |
Capex to Sales |
0.02 | 0.00 | 0.00 | 0.46 | 0.49 | 0.17 | 0.89 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.48 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.30 | 0.28 | 1.85 | 3.16 | 2.76 | 3.54 | 2.77 | 0.97 | 0.35 | 0.14 |
Cash ROIC |
(50.60%) | (79.31%) | (38.79%) | (14.74%) | (33.25%) | (47.00%) | (3.32%) | (21.06%) | (17.75%) | (23.57%) |
Accounts Receivable Turnover |
2.51 | 0.95 | 2.88 | 0.04 | 0.05 | 0.08 | 0.04 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
13.16 | 16.88 | 19.79 | 20.38 | 17.06 | 22.03 | 15.97 | 5.54 | 7.27 | 8.81 |
Average Payables |
6.38 | 8.95 | 9.02 | 8.12 | 5.31 | 5.26 | 2.36 | 1.51 | 3.65 | 12.46 |
Average Assets |
58.76 | 73.48 | 78.01 | 87.77 | 99.37 | 107.94 | 388.77 | 433.56 | 319.25 | 593.37 |
Average Common Equity |
4.23 | 4.16 | 25.96 | 67.65 | 79.16 | 81.37 | 104.97 | 102.17 | 233.22 | 523.80 |
Columns are period end dates